Action A095700 GENEXINE, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Genexine, Inc.

Actions

A095700

KR7095700001

Cours en clôture Korea S.E.
Autres places de cotation
 00:00:00 26/04/2024 		Varia. 5j. Varia. 1 janv.
7 280 KRW -0,95% Graphique intraday de Genexine, Inc. +3,41% -26,46%
2023 Genexine, Inc. annonce ses résultats pour le troisième trimestre et les neuf mois terminés le 30 septembre 2023 CI
2023 Genexine, Inc. et PT Kalbe Genexine Biologics reçoivent la première autorisation de mise sur le marché de leur nouvelle érythropoïétine à action prolongée, l'Efepoetin Alfa, de la part de l'autorité indonésienne des aliments et des médicaments (BPOM) CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
Sector Update: Health Care
Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday
I-Mab's Phase 3 Trial of Growth Hormone Deficiency Drug Meets Primary Endpoint, Joint Venture Partner Says
Genexine Announces Positive Topline Results from the Multi-Center, Randomized, Open-Label, Active-Controlled Pivotal Phase 3 Study
Henlius Biotech Grants Hansizhuang License to Kalbe Genexine Biologics
Genexine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Genexine abstract on GX-188E and GX-I7 triple combination therapy in HNSCC is released at 2023 ASCO Annual Meeting
Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Genexine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for its promising DNA vaccine for advanced cervical cancer
Genexine Receives Fast Track Designation from Korean Health Authority for Its Promising DNA Vaccine for Advanced Cervical Cancer
Genexine, Inc. to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference
Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Genexine to Raise $70 Million via Share Issuance
Genexine’s Announces that DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer
Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congr
Genexine to Present Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology Congress 2022
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action A095700
  4. Actualités Genexine, Inc.
  5. Autres langues